Skip to database content
GlobalRPh Clinical Reference Platform
Infectious diseases and clinical microbiology
Version 1.6 | August 28, 2026

Bacterial Pathogen Database and Treatment Coverage Explorer

Search organisms by modern taxonomy, Gram reaction, morphology, oxygen requirements, syndrome, specimen, resistance phenotype, or former name. Move in either direction from organism to disease or disease to likely pathogens, then open the syndrome-specific empiric therapy module, review adult, pediatric, neonatal, and renal dosing references without adult fallback, or evaluate multi-organism directed coverage using the fewest reasonable agents.

Clinical-use boundary: This platform is an educational and clinical-reference aid, not a prescribing system. Treatment depends on the infection site, illness severity, patient age and weight, pregnancy, allergy phenotype, renal and hepatic function, interactions, source control, local antibiogram, isolate susceptibility, MIC method and breakpoint version, and current institutional guidance. Seek infectious-diseases, microbiology, pharmacy, surgery, infection-prevention, or public-health consultation when indicated.

Searchable organism database

Browse current names and former taxonomy, clinically important resistance phenotypes, culture and diagnostic details, likely infections, MIC cautions, directed-therapy anchors, prevention, and public-health notes.

Return to top

Disease and syndrome atlas

Start with a clinical syndrome, then review ranked bacterial causes, context modifiers, specimens, culture strategy, diagnostic cautions, empiric-treatment anchors, source control, red flags, and links back to organism profiles.

Return to top

Multi-organism treatment coverage optimizer

Select cultured or suspected organisms. The engine searches stored complete regimen sets and ranks combinations that cover every eligible selection with the fewest agents, followed by narrower spectrum and preferred directed options.

0 selected
Do not use this engine as stand-alone empiric prescribing advice. It does not know the patient, infection site, MIC values, local antibiogram, dose, exposure target, source control, or whether every selected isolate is clinically significant. Specialist-only, multidrug, topical, and local-therapy profiles are excluded from automatic minimization.

1. Select up to eight organisms or phenotypes

2. Review selections and constraints

Clinical context, route, and maximum agents
Conservative screening constraints
Select organisms and run the analysis.
Return to top

MIC and antimicrobial-susceptibility workspace

Document a raw MIC and the laboratory-reported category, then review organism-specific intrinsic resistance, MIC cautions, and current standard links. The application does not reproduce proprietary breakpoint tables or invent an interpretation.

CLSI M100 Ed36 | EUCAST v16.1
An MIC is not self-interpreting. The same number may be interpreted differently by organism, antimicrobial, method, specimen site, dosing exposure, standard, and version. Confirm the laboratory's implemented breakpoints and any susceptible-dose-dependent or increased-exposure requirements.

Enter an isolate result

Enter a result to begin.

Organism context

Optional local breakpoint import

A laboratory or health system can create its own version-controlled JSON file from standards it is licensed and authorized to implement. The file is processed locally in the browser and is not uploaded.

Expected JSON schema
{
  "standard": "CLSI",
  "version": "M100 Ed36",
  "breakpoints": [
    {
      "organismId": "example-organism-id",
      "drugId": "example-drug-id",
      "method": "broth microdilution",
      "site": "nonmeningitis",
      "unit": "ug/mL",
      "sMax": 1,
      "iMin": 2,
      "iMax": 2,
      "rMin": 4
    }
  ]
}
Return to top

Antimicrobial reference library

Review spectrum, route, AWaRe group, population-specific dosing availability, renal considerations, cautions, and the organism regimens that use each agent. Open the linked dosing reference for adult, pediatric, neonatal, non-dialysis renal, hemodialysis, or CRRT orientation.

Return to top

Guidelines, standards, textbooks, and source library

Every profile is connected to dated sources. Current AST standards and treatment guidance are separated from broad textbook background so users can see which material is likely to change fastest.

Current standards in this release: CLSI M100 Ed36, the March 2026 CLSI Breakpoint Implementation Toolkit, EUCAST breakpoint tables v16.1, and IDSA AMR guidance published July 30, 2026. A standard link is not permission to reproduce copyrighted tables; users must access and implement the applicable source lawfully.
Return to top

Legacy-page clinical and taxonomy audit

The attached GlobalRPh pages were used as historical requirements and content examples. This register identifies high-value material that was preserved, renamed, corrected, separated into species-specific records, or removed because it could not be validated.

Return to top

About the platform and V1.0-to-V1.6 review

Version 1.6 is a data-driven replacement for a collection of static organism pages and now includes a population-separated antimicrobial dosing reference. The platform retains the original clinical intent while making taxonomy, evidence dates, disease links, AST cautions, and maintenance explicit.

Release 2026-08-28

What is included

  • Searchable organism and resistance-phenotype profiles with current names and legacy aliases.
  • Independent classifications for Gram reaction, morphology, oxygen requirement, functional group, taxonomy, reservoir, and transmission.
  • Culture, specimen, diagnostic, MIC, intrinsic-resistance, resistance-mechanism, treatment, prevention, infection-control, biosafety, and public-health fields.
  • A disease atlas that ranks pathogens by syndrome and context, links bidirectionally to organism profiles, and opens complete empiric-treatment scenarios.
  • A separate empiric therapy module with setting, severity, resistance-risk, diagnostic, source-control, duration, monitoring, and de-escalation branches.
  • A population-separated dosing reference for adults, pediatric patients, and neonates, plus adult non-dialysis renal, intermittent hemodialysis, and CRRT orientation. Missing pediatric or neonatal data never fall back to an adult dose.
  • A regimen-set coverage optimizer that searches for complete coverage with the fewest eligible agents.
  • An MIC workspace that refuses to invent a breakpoint and supports optional local version-controlled data.
  • Guideline, textbook, PubMed-search, and NCBI-taxonomy links plus a transparent legacy audit.

Scope and important limits

This is a broad clinician-facing seed database, not an exhaustive catalogue of every validly published bacterial species, subspecies, strain, resistance determinant, or regional syndrome. Aggregate records are used where species-level management is usually driven by the syndrome and susceptibility result. Rare and high-consequence organisms are flagged for reference-laboratory, public-health, or specialist review.

The coverage optimizer minimizes stored regimen sets, not patient harm. Fewer agents are not always safer or more appropriate; combination therapy may be required for synergy, resistance prevention, toxin suppression, or a protected site. Conversely, a broad single agent may be less desirable than two narrow agents. The result therefore displays stewardship scoring and required verification rather than a single directive.

V1.0 review findings and V1.6 improvements

Recommended editorial maintenance cycle

  1. Check CLSI M100, EUCAST tables, IDSA AMR guidance, FDA safety or labeling changes, CDC public-health guidance, and major society guidelines at least annually and after high-impact interim updates.
  2. Update the source record first, then organism, disease, antimicrobial, and legacy-audit records that depend on it.
  3. Run schema, cross-link, duplicate-ID, regimen-ID, source-ID, PHP, JavaScript, accessibility, and browser smoke tests before deployment.
  4. Retain old names as aliases and document clinically meaningful changes rather than silently overwriting history.
Return to top

Details